Key Takeaways
- ARCH Venture Partners raised $53.0M from ARCH Venture Partners.
- Sector: Biotechnology & Life Sciences.
- Geography: United States.
Analysis
SciNeuro Pharmaceuticals, a clinical-stage biotechnology company focused on neurodegenerative diseases, closed an equity financing totaling $53 million, led by LAV and ARCH Venture Partners, with participation from new and existing investors.
Proceeds will accelerate development across its CNS pipeline, targeting pathways including Lp-PLA2, beta-amyloid, and LRRK2, as the company expands its discovery efforts in CNS disorders.
In addition, the company was awarded a $5 million non-dilutive research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to de-risk early-stage work.
As part of its next growth phase, Hogan Wan has been named CFO, bringing more than a decade and a half of biopharma finance and M&A experience to SciNeuro’s leadership team.
Mr. Wan previously led investor relations and strategy at Ascentage Pharma and held senior financial roles at Goldman Sachs, J.P. Morgan, and UBS Investment Bank; earlier he helped build CBC Group’s healthcare investments.
Investors have shown heightened interest in early-stage CNS programs, with top-tier life-sciences funds backing portfolio companies to accelerate translation from preclinical models to clinical trials. SciNeuro’s financing exemplifies how focused specialist funds and strategic grants can de-risk early development and speed patient access.
With this funding, SciNeuro is positioned to advance its pipeline, move toward clinical milestones, and broaden its partnerships with academic and biopharma collaborators as it seeks to bring novel neuroprotective therapies to patients.